Jefferies Financial Group Equities Analysts Lift Earnings Estimates for Genmab A/S (NASDAQ:GMAB)

Genmab A/S (NASDAQ:GMABGet Rating) – Jefferies Financial Group boosted their Q2 2022 earnings estimates for shares of Genmab A/S in a research note issued to investors on Wednesday, May 11th. Jefferies Financial Group analyst P. Welford now forecasts that the company will post earnings of $0.23 per share for the quarter, up from their prior forecast of $0.16. Jefferies Financial Group also issued estimates for Genmab A/S’s Q3 2022 earnings at $0.23 EPS and Q4 2022 earnings at $0.37 EPS.

GMAB has been the topic of several other reports. Morgan Stanley cut their price objective on Genmab A/S from $33.00 to $30.00 and set an “underweight” rating on the stock in a research report on Tuesday, April 12th. JPMorgan Chase & Co. dropped their price objective on Genmab A/S from 3,200.00 to 3,100.00 in a research note on Friday, February 25th. Bryan, Garnier & Co raised Genmab A/S from a “sell” rating to a “neutral” rating and set a 2,100.00 target price for the company in a research note on Friday. Zacks Investment Research lowered Genmab A/S from a “hold” rating to a “sell” rating in a research report on Thursday, January 20th. Finally, SVB Leerink dropped their target price on Genmab A/S from $42.00 to $39.00 and set a “market perform” rating on the stock in a report on Thursday, February 17th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $611.56.

Shares of NASDAQ GMAB opened at $28.32 on Friday. Genmab A/S has a 1-year low of $27.42 and a 1-year high of $49.07. The company has a 50-day moving average of $34.97 and a two-hundred day moving average of $36.82. The company has a market cap of $18.62 billion, a PE ratio of 38.79, a P/E/G ratio of 1.34 and a beta of 0.98.

Genmab A/S (NASDAQ:GMABGet Rating) last posted its quarterly earnings results on Wednesday, February 16th. The company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.13 by $0.04. Genmab A/S had a return on equity of 14.23% and a net margin of 35.58%. The business had revenue of $402.74 million during the quarter, compared to analyst estimates of $387.16 million.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. increased its holdings in Genmab A/S by 1.6% during the first quarter. BlackRock Inc. now owns 5,494,689 shares of the company’s stock valued at $198,799,000 after buying an additional 86,571 shares during the period. Stifel Financial Corp increased its stake in Genmab A/S by 1.1% during the fourth quarter. Stifel Financial Corp now owns 1,209,423 shares of the company’s stock valued at $47,844,000 after purchasing an additional 12,587 shares during the last quarter. Hardman Johnston Global Advisors LLC raised its holdings in Genmab A/S by 0.9% during the 3rd quarter. Hardman Johnston Global Advisors LLC now owns 1,079,269 shares of the company’s stock worth $47,164,000 after buying an additional 10,013 shares during the period. Renaissance Technologies LLC raised its holdings in Genmab A/S by 19.5% during the 4th quarter. Renaissance Technologies LLC now owns 1,074,400 shares of the company’s stock worth $42,503,000 after buying an additional 175,600 shares during the period. Finally, Royal Bank of Canada boosted its position in Genmab A/S by 6.6% during the third quarter. Royal Bank of Canada now owns 623,330 shares of the company’s stock worth $27,240,000 after purchasing an additional 38,585 shares during the period. 5.92% of the stock is owned by institutional investors.

About Genmab A/S (Get Rating)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Further Reading

Earnings History and Estimates for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.